(Reuters) -Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near ...
Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...
Hosted on MSN
Senate unanimously approves bill to 'replace outdated animal testing,' still awaiting House
The phaseout of animal testing in federally funded research moved one step closer to completion with the Senate's unanimous approval of the FDA Modernization Act 3.0 (S-355) on Tuesday. The one-page ...
The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological products and drugs, instead moving toward alternative testing models such ...
Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...
The National Institutes of Health announced last week that it will no longer issue funding calls for grant proposals that rely solely on animal testing. Moving forward, all such calls must also ...
The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...
Administrator Lee Zeldin plans to revive a ban on animal testing at the Environmental Protection Agency, The Washington Times has learned. The EPA had pursued a phaseout of animal testing during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback